Clinical activity of HER3-DXd, an ADC targeting HER3, has been observed independent of the resistance mechanism in a phase I clinical trial involving patients resistant to EGFR-TKIs, suggesting a novel approach for treating EGFR-TKI-resistant NSCLC patients (79). Here, EGFR is linked to non-small cell lung carcinoma.